Signal active
Investment Firm
Overview
Agilent provides laboratory solutions to meet the needs of analytical scientists and clinical researchers worldwide. Agilent works closely with customers to help address global trends that impact human health and the environment and to anticipate future scientific needs. Agilent's solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management.
Highlights
1999
Biotechnology
10001+
37
6
10
Private Equity, Early Stage Venture, Late Stage Venture, Seed
N/A
Location
Santa Clara, California, United States, North America
Contact Information
Social
Profile Resume
Agilent Technologies, established in 1999 and headquartered in United States, North America., specializes in Private Equity, Early Stage Venture, Late Stage Venture, Seed investments across Biotechnology, Manufacturing, Genetics, Developer Tools, Service Industry, Optical Communication, Financial Services, Venture Capital, Finance, Angel Investment. The organization boasts a portfolio of 37 investments, with an average round size of $34.4M and 10 successful exits. Their recent investments include Gen9, Big Bear Networks, Sequoia Capital, Oak Investment Partners, Accel. The highest investment round they participated in was $129.4B. Among their most notable exits are Gen9 and Big Bear Networks. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
37
5
6
10
Investments
37
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
Sep 06, 2023 | Halo X Ray Technologies | Industrial Automation | 2.5M |
Apr 03, 2024 | Biofidelity | Biotechnology | 24.0M |
May 14, 2024 | Elegen | Biotechnology | 35.0M |
Jun 27, 2024 | RareCyte | Biotechnology | 20.0M |
Exits
10
Funding Timeline
37
0
0
Funding Rounds
37
Agilent Technologies has raised 37 rounds. Their latest funding was raised on Jun 27, 2024 from a Venture Round - RareCyte round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
Sep 06, 2023 | Series A - Halo X Ray Technologies | - | 2.5M | - |
Apr 03, 2024 | Venture Round - Biofidelity | - | 24.0M | - |
May 14, 2024 | Series B - Elegen | - | 35.0M | - |
Jun 27, 2024 | Venture Round - RareCyte | - | 20.0M | - |
Investors
1
Investor Name | Lead Investor | Funding Round | Money Raised |
---|---|---|---|
- | No | Post-IPO Debt - Agilent Technologies | 500.0M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
News
Sep 13, 2024
Yahoo Finance - Those who invested in Agilent Technologies (NYSE:A) five years ago are up 85%
News
Aug 21, 2024
SeekingAlpha - Agilent Technologies Non-GAAP EPS of $1.32 beats by $0.06, revenue of $1.58B beats by $20M
News
Aug 20, 2024
Yahoo Finance - Agilent Technologies (NYSE:A) jumps 5.8% this week, though earnings growth is still tracking behind five-year shareholder returns
News
Jul 23, 2024
Genetic Engineering and Biotechnology News - Agilent to Acquire Biovectra for $925M, Expanding CDMO Portfolio
News
Jul 22, 2024
Genetic Engineering and Biotechnology News - Agilent to Acquire Biovectra for $925M, Expanding CDMO Portfolio
News
Jul 22, 2024
Endpoints News - Agilent Technologies to acquire CDMO Biovectra for $925M